Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity.
Pete Lyons, MBA
Advertisement
Pete Lyons, MBA, is vice chair and US Life Sciences leader at Deloitte.
Articles by Pete Lyons, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
5